Trial Profile
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration; Wet age-related macular degeneration
- Focus Therapeutic Use
- 26 Oct 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 27 Jun 2016 New trial record